BPC-157 and TB-500 are the most discussed regenerative peptides in longevity circles. Here is what the animal research shows, how practitioners use them, and what you need to know about safety and sourcing.
BPC-157 / TB-500 (Moderate evidence) — two of the most discussed compounds in the intersection of regenerative medicine and longevity. Their appeal is straightforward: faster recovery from injuries means more consistent exercise, and consistent exercise is the single most impactful longevity intervention available. An athlete sidelined for months with a torn tendon or a weekend warrior nursing chronic tendinopathy cannot train, and the compounding effect of missed training weeks is significant over years and decades.
The challenge with discussing these peptides honestly is that the enthusiasm in the longevity community has dramatically outpaced the evidence base. BPC-157 has extensive and genuinely impressive animal research. TB-500 (synthetic thymosin beta-4) has solid wound healing data. But neither has a single published, peer-reviewed, randomized controlled trial in humans for injury recovery. This does not mean they do not work. It means we do not have the standard of evidence that normally precedes widespread adoption of a therapeutic compound.
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. It was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb, who have published the majority of the research on this compound. Their work, spanning over two decades, has demonstrated healing effects across a remarkable range of tissue types in animal models.
What the animal research shows:
A comprehensive review by Sikiric et al. published in Current Neuropharmacology documented BPC-157's effects across multiple injury types:
The mechanism appears to involve modulation of the nitric oxide system, promotion of angiogenesis (new blood vessel formation), growth hormone receptor upregulation, and activation of the FAK-paxillin signaling pathway that governs cell migration and tissue repair. For the broader context of how peptides fit into longevity strategies, see our BPC-157 / TB-500 intervention page (Moderate evidence).
The critical caveat: All of this data comes from animal models. The dose translation from rats to humans is not straightforward, the injury models are artificially created, and the endpoints measured in animals do not always predict human outcomes. Dr. Sikiric's group has conducted the vast majority of BPC-157 research, which means the findings have not been widely replicated by independent laboratories.
TB-500 is a synthetic version of thymosin beta-4, a naturally occurring 43-amino acid peptide found in virtually all human cells. Thymosin beta-4 plays a fundamental role in cell migration, wound healing, and tissue repair. Unlike BPC-157, which was identified in gastric juice, thymosin beta-4 is well-characterized in mainstream medical literature.
Research highlights:
How TB-500 differs from BPC-157:
Many longevity practitioners and biohackers combine BPC-157 and TB-500, reasoning that the complementary mechanisms may produce synergistic healing effects. It is important to emphasize that no clinical trial has tested this combination in humans. The following protocols are based on practitioner experience and community reports, not published evidence.
BPC-157 Protocol:
TB-500 Protocol:
Combination Protocol:
FDA Position:
The FDA has issued warnings about peptide products sold through unregulated channels. BPC-157 and TB-500 are not FDA-approved for any indication, and the FDA has specifically targeted peptide sellers making therapeutic claims. In 2023, the FDA reclassified certain peptides under the Prescription Drug Marketing Act, making some peptides harder to obtain through compounding pharmacies.
Quality and Purity Concerns:
This is perhaps the most critical practical issue with peptides. Because these compounds are not manufactured under FDA oversight for human use, the quality of available products varies enormously:
Potential risks:
One of the more surprising aspects of BPC-157 is that oral administration appears to be effective in animal studies, which is unusual for a peptide (most peptides are degraded by digestive enzymes). BPC-157's gastric origin may explain its unusual stability in the GI tract.
| Route | Bioavailability | Convenience | Safety | Evidence Level |
|-------|----------------|-------------|--------|---------------|
| Oral capsules | Lower but functional | High | Safest | Animal data |
| Sublingual | Moderate | High | Safe | Very limited data |
| Subcutaneous injection | Highest (local) | Low | Requires sterile technique | Animal data |
| Intramuscular injection | High (systemic) | Low | Requires sterile technique | Animal data |
For those uncomfortable with self-injection, oral BPC-157 capsules (250-500 mcg) represent a more accessible option, particularly for gut-related applications. For localized injury healing, injection near the injury site may be more effective based on the animal data showing local tissue effects.
The indirect longevity argument for regenerative peptides is compelling: injuries disrupt training, training disruption reduces fitness, and reduced fitness accelerates aging. If BPC-157 and TB-500 can meaningfully accelerate injury recovery and reduce downtime, the cumulative effect on exercise consistency over decades could translate to real healthspan gains.
Peter Attia has discussed the importance of maintaining training consistency as a longevity strategy, noting that the ability to recover from injuries and return to training quickly becomes increasingly important with age. Andrew Huberman has discussed BPC-157's mechanisms on his podcast, highlighting the growth hormone receptor upregulation and nitric oxide modulation pathways.
However, it is equally important to note that no longevity researcher has cited peptide therapy as a primary longevity intervention. It is, at best, a supportive tool for maintaining the exercise consistency that drives real longevity benefits.
BPC-157 and TB-500 represent fascinating compounds with genuinely impressive preclinical data and a growing body of practitioner experience. The animal research on tissue repair is extensive and consistent, and the theoretical mechanisms are well-characterized. However, the complete absence of human RCTs, the regulatory uncertainty, and the quality control challenges of an unregulated market mean these compounds carry more risk and uncertainty than most longevity interventions. If you choose to experiment with them, source from reputable suppliers with verifiable COAs, start with conservative dosing, work with a physician experienced in peptide therapy, and maintain realistic expectations about what the evidence actually supports.